Cargando…
Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
Parkinson’s disease (PD) is the most common movement disorder and the second most prevalent neurodegenerative disease after Alzheimer’s disease. Despite decades of research, there is still no cure for PD and the complicated intricacies of the pathology are still being worked out. Much of the researc...
Autores principales: | Miller, Sean J., Campbell, Cameron E., Jimenez-Corea, Helen A., Wu, Guan-Hui, Logan, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9063319/ https://www.ncbi.nlm.nih.gov/pubmed/35516803 http://dx.doi.org/10.3389/fnins.2022.824191 |
Ejemplares similares
-
Neuroglial Plasticity at Striatal Glutamatergic Synapses in Parkinson's Disease
por: Villalba, Rosa M., et al.
Publicado: (2011) -
Senescence and Senolytics: State of the Art on Cellular Senescence, Senolytics, and Healthspan
por: Campisi, Judith
Publicado: (2020) -
Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease
por: Miller, Sean J., et al.
Publicado: (2023) -
Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
por: Alecu, Irina, et al.
Publicado: (2019) -
Connexin-Dependent Neuroglial Networking as a New Therapeutic Target
por: Charvériat, Mathieu, et al.
Publicado: (2017)